Sign in
Taking peopleNo phase

Early signs of wear in replaced heart valves for aortic stenosis

Scans for early wear of replaced valves in aortic stenosis.

Key facts

Who runs it
St. Antonius Hospital
Where
Edinburgh, United KingdomSee the siteAlso in 2 other countries, 3 sites
Trial code
Registry title
The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI)
Status
Recruiting
People taking part
180 people, planned
Started
16 Nov 2023
Planned end
1 Oct 2026
Type of study
Observational, 2 groups
Treatments tested
  • 18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)
Record updated
19 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a successful TAVI (aortic valve replacement through a catheter) about 5 years ago. It uses scans to look for early signs of valve wear.

Age
18 Years and older
Sex
All
Disease stage
Aortic valve stenosis (narrowed aortic valve) treated with TAVI about 5 years ago.
Earlier treatment
Must have had a successful TAVI with a Sapien or CoreValve Evolut valve about 5 years ago. Cannot have used blood-thinning pills (oral anticoagulation), short or long term, after TAVI.

Main reasons for not taking part

  • Use of oral anticoagulation (blood-thinning pills) at any time after TAVI
  • Known severe kidney failure
  • Known severe leak around the new valve (paravalvular regurgitation)
  • A past valve-in-valve procedure
  • Any repeat procedure on the aortic valve, including closing a leak around the valve

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Successful TAVI with Sapien or CoreValve Evolut prosthesis about 5 years ago
  • Able to undergo hybrid 18F-NaF PET-CT imaging and transthoracic echocardiography
  • Written informed consent

Who cannot take part

  • Known severe renal insufficiency
  • History of valve-in-valve procedure
  • History of aortic valve re-intervention (including percutaneous paravalvular leak closure)
  • Temporary or chronic oral anticoagulation use after TAVI
  • Known severe paravalvular regurgitation

Where in United Kingdom

Also in 2 other countries, 3 sites

  • University of EdinburghEdinburgh, United KingdomContact: Prof. M. Dweck, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

A multicentre cross-sectional cohort study to assess the difference in bioprosthetic micro-calcification activity, detected with 18F-NaF PET-CT, as early marker of transcatheter valve degeneration, between patients with vs. without subclinical leaflet thrombosis at five years after TAVI; and between patients with intra-annular vs. supra-annular TAVI prostheses.

The 2 groups in the trial

  • Intra-annular

    Patients with an intra-annular Sapien TAVI prosthesis

    Treatment: 18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)

  • Supra-annular

    Patients with a supra-annular CoreValve Evolut TAVI prosthesis

    Treatment: 18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration
Plain-language title
Early signs of wear in replaced heart valves for aortic stenosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 May 2026